Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

Cancer discovery·2026

Same author

Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.

JCO precision oncology·2026

Same author

Magnesium as a conformational gatekeeper of KRAS: Structural dynamics and therapeutic implications.

Protein science : a publication of the Protein Society·2026

Same author

Magnesium as a Conformational Gatekeeper of KRAS: Structural Dynamics and Therapeutic Implications.

bioRxiv : the preprint server for biology·2026

Same author

Kinetic model of radiochemical oxygen depletion (ROD) in FLASH radiotherapy.

Medical physics·2026

Same author

Integration of Immune Checkpoint Blockade With Radiation in Lung Cancer: Lessons From Recent Trials.

International journal of radiation oncology, biology, physics·2026

Search research articles

Related Experiment Video

Updated: May 22, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Proton SBRT for medically inoperable stage I NSCLC.

Kenneth D Westover¹, Joao Seco, Judith A Adams

¹Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer

|May 4, 2012

Summary

Proton stereotactic body radiation therapy (SBRT) shows promise for medically inoperable stage I non-small-cell lung cancer (NSCLC). This study found proton SBRT to be effective and well-tolerated in an unfavorable patient group.

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Experiment Videos

Last Updated: May 22, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

Radiation Oncology
Medical Physics
Thoracic Oncology

Background:

Proton beam radiation offers potential advantages for non-small-cell lung cancer (NSCLC) treatment.
The efficacy of proton stereotactic body radiation therapy (SBRT) for medically inoperable stage I NSCLC is not well-established.

Purpose of the Study:

To evaluate the outcomes and toxicity of proton SBRT in patients with medically inoperable stage I NSCLC.

Main Methods:

Retrospective analysis of 15 patients with medically inoperable stage I NSCLC treated with proton SBRT.
Treatments involved 2-3 proton beams, delivered at 42-50 Gy (RBE) in 3-5 fractions.
Toxicity assessed using Common Toxicity Criteria for Adverse Events version 4.

Main Results:

Fifteen patients and 20 tumors were treated between July 2008 and September 2010.
Treatments were generally well-tolerated, with manageable toxicities including fatigue, dermatitis, rib fractures, and pneumonitis.
At a median follow-up of 24.1 months, 2-year overall survival was 64% and local control was 100%.

Conclusions:

Proton SBRT is an effective and well-tolerated treatment option for medically inoperable stage I NSCLC patients.
Further prospective clinical trials are recommended to confirm the utility of proton SBRT for stage I NSCLC.